EA030276B1 - Способы идентификации страдающих раком пациентов и лечения рака у пациентов, у которых имеется или развивается резистентность к первой терапии рака - Google Patents

Способы идентификации страдающих раком пациентов и лечения рака у пациентов, у которых имеется или развивается резистентность к первой терапии рака Download PDF

Info

Publication number
EA030276B1
EA030276B1 EA201290883A EA201290883A EA030276B1 EA 030276 B1 EA030276 B1 EA 030276B1 EA 201290883 A EA201290883 A EA 201290883A EA 201290883 A EA201290883 A EA 201290883A EA 030276 B1 EA030276 B1 EA 030276B1
Authority
EA
Eurasian Patent Office
Prior art keywords
kinase
cancer
protein kinase
protein
inhibitor
Prior art date
Application number
EA201290883A
Other languages
English (en)
Russian (ru)
Other versions
EA201290883A1 (ru
Inventor
Леви А. Гаррауэй
Кори М. Йоханнессен
Original Assignee
Дана-Фарбер Кэнсер Инститьют, Инк.
Дзе Брод Инститьют, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дана-Фарбер Кэнсер Инститьют, Инк., Дзе Брод Инститьют, Инк. filed Critical Дана-Фарбер Кэнсер Инститьют, Инк.
Publication of EA201290883A1 publication Critical patent/EA201290883A1/ru
Publication of EA030276B1 publication Critical patent/EA030276B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11024—Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EA201290883A 2010-03-09 2011-03-09 Способы идентификации страдающих раком пациентов и лечения рака у пациентов, у которых имеется или развивается резистентность к первой терапии рака EA030276B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31219310P 2010-03-09 2010-03-09
US31251910P 2010-03-10 2010-03-10
US32602110P 2010-04-20 2010-04-20
US41556910P 2010-11-19 2010-11-19
PCT/US2011/027689 WO2011112678A1 (en) 2010-03-09 2011-03-09 Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy

Publications (2)

Publication Number Publication Date
EA201290883A1 EA201290883A1 (ru) 2013-04-30
EA030276B1 true EA030276B1 (ru) 2018-07-31

Family

ID=43837946

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290883A EA030276B1 (ru) 2010-03-09 2011-03-09 Способы идентификации страдающих раком пациентов и лечения рака у пациентов, у которых имеется или развивается резистентность к первой терапии рака

Country Status (12)

Country Link
US (3) US20130059851A1 (enExample)
EP (1) EP2545187B1 (enExample)
JP (1) JP5985401B2 (enExample)
KR (1) KR20120139767A (enExample)
CN (1) CN103038364A (enExample)
AU (1) AU2011224410B2 (enExample)
BR (1) BR112012022801B8 (enExample)
CA (1) CA2791247C (enExample)
EA (1) EA030276B1 (enExample)
ES (1) ES2714875T3 (enExample)
MX (1) MX343368B (enExample)
WO (1) WO2011112678A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
US20140296248A1 (en) * 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
US10202643B2 (en) 2011-10-31 2019-02-12 University Of Utah Research Foundation Genetic alterations in glioma
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
EA028135B1 (ru) * 2012-03-28 2017-10-31 Дана-Фарбер Кэнсер Инститьют, Инк. Мутанты c-raf, придающие резистентность к ингибиторам raf
EP2884979B1 (en) 2012-08-17 2019-06-26 F.Hoffmann-La Roche Ag Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
HK1212216A1 (en) 2012-10-23 2016-06-10 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
HK1211887A1 (en) 2013-02-04 2016-06-03 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2014150671A1 (en) * 2013-03-15 2014-09-25 The Broad Institute, Inc. Methods of identifying responses to map kinase inhibition therapy
WO2014204261A1 (ko) * 2013-06-21 2014-12-24 사회복지법인 삼성생명공익재단 Tpl2의 발현억제제 또는 활성억제제를 유효성분으로 포함하는 신세포암의 예방 또는 치료용 약학적 조성물
CA2960702A1 (en) * 2014-09-17 2016-03-24 Institut Curie Map3k8 as a marker for selecting a patient affected with an ovarian cancer for a treatment with a mek inhibitor
KR20160129609A (ko) 2015-04-30 2016-11-09 삼성전자주식회사 Ｂｒａｆ 저해제를 포함하는 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도
MX370984B (es) 2015-07-06 2020-01-09 Gilead Sciences Inc Moduladores de cáncer de tiroides de osaka (cot) y métodos de uso de los mismos.
KR20200022527A (ko) 2015-07-06 2020-03-03 길리애드 사이언시즈, 인코포레이티드 Cot 조정제로서의 6-아미노-퀴놀린-3-카르보니트릴
GB201520178D0 (en) * 2015-11-16 2015-12-30 Univ London Queen Mary Method
CN105695616A (zh) * 2016-04-22 2016-06-22 王冬国 诊断甲状腺癌的分析标志物及其应用
JP6776378B2 (ja) 2016-06-30 2020-10-28 ギリアード サイエンシーズ， インコーポレイテッド Ｃｏｔモジュレーターとしての４，６−ジアミノキナゾリン類およびその使用方法
WO2018027223A1 (en) * 2016-08-05 2018-02-08 Duke University Camkk2 inhibitor compositions and methods of using the same
JP7190432B2 (ja) * 2016-12-20 2022-12-15 イーティーエイチ・チューリッヒ がんにおける非遺伝的薬物耐性プログラムを標的とする薬物の同定
US10793901B2 (en) * 2016-12-28 2020-10-06 Roche Molecular Systems, Inc. Reversibly protected nucleotide reagents with high thermal stability
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
WO2019090020A1 (en) * 2017-11-02 2019-05-09 University Of Georgia Research Foundation, Inc. Methods and compositions related to increased rotavirus production
CN108872438B (zh) * 2018-08-06 2021-01-15 杭州迪相实业有限公司 一种外泌体中肺癌标志物gk5快速检测试剂盒
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020176693A2 (en) * 2019-02-26 2020-09-03 Cell Response, Inc. Methods for treating map3k8 positive cancers
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CN110862968A (zh) * 2019-10-30 2020-03-06 中国农业科学院兰州兽医研究所 Map3k8基因敲除pk-15细胞系的构建方法及其应用
EP4126231A1 (en) 2020-03-30 2023-02-08 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
WO2021202688A1 (en) 2020-04-02 2021-10-07 Gilead Sciences, Inc. Process for preparing a cot inhibitor compound
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US12173039B1 (en) 2021-01-08 2024-12-24 Washington University TPL2 inhibiting agents, uses thereof, and detection of TPL2
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1803821A2 (en) * 2002-06-05 2007-07-04 Cedars-Sinai Medical Center Methods for managing kinase inhibitor therapy
WO2010068738A1 (en) * 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982001011A1 (en) 1980-09-24 1982-04-01 Corp Cetus Diagnostic method and probe
DE3381518D1 (de) 1982-01-22 1990-06-07 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
AT404556B (de) 1995-11-23 1998-12-28 Pharma Consult Gmbh Einrichtung zum dichten verschliessen eines glas- oder kunststoffbehälters zur aufnahme flüssiger pharmazeutischer produkte
GB2323845A (en) 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
DE69836378T2 (de) 1997-07-01 2007-10-11 Warner-Lambert Co. Llc Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren
US6821963B2 (en) 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
BR9810366A (pt) 1997-07-01 2000-08-29 Warner Lambert Co Derivados de ácido 4-bromo ou 4-iodo fenilamino benzidroxîmico e seu uso como inibidores de mek
US20040171632A1 (en) 1998-12-22 2004-09-02 Gowan Richard Carleton Combination chemotherapy
HK1042057A1 (zh) 1998-12-22 2002-08-02 沃尼尔‧朗伯公司 联合化学疗法
JP2000204079A (ja) 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
CA2349467A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
JP2000212157A (ja) 1999-01-13 2000-08-02 Warner Lambert Co ジアリ―ルアミン
BR9916896A (pt) 1999-01-13 2001-11-20 Warner Lambert Co Diaril aminas substituìdas com 1-heterociclo
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
BR9916885A (pt) 1999-01-13 2001-11-20 Warner Lambert Co Derivados de benzeno-sulfonamida e seu uso comoinibidores da mek
JP2000204075A (ja) 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
EE200100373A (et) 1999-01-13 2002-10-15 Warner-Lambert Company Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
JP2000204077A (ja) 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
HU230251B1 (hu) 2000-07-19 2015-11-30 Warner-Lambert Co. 4-Jód-fenil-amino-benzhidroxámsav-észter-származékok és ezeket tartalmazó gyógyászati készítmények
JP4602667B2 (ja) 2001-10-23 2010-12-22 メルク セローノ ソシエテ アノニム アゾール誘導体および該アゾール誘導体を含有する医薬組成物
JP2005526008A (ja) 2001-12-04 2005-09-02 オニックス ファーマシューティカルズ，インコーポレイティド 癌を処置するためのｒａｆ−ｍｅｋ−ｅｒｋ経路インヒビター
WO2003047583A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours
AU2002347360A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
BR0307060A (pt) 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
US20030216460A1 (en) 2002-03-13 2003-11-20 Wallace Eli M. N3 alkylated benzimidazole derivatives as MEK inhibitors
US6989451B2 (en) 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
EP1545529A4 (en) 2002-09-30 2010-03-03 Bristol Myers Squibb Co NEW TYROSINE KINASE HEMMER
AU2003287366A1 (en) 2002-10-31 2004-06-07 University Of Rochester Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
AU2003291268A1 (en) 2002-11-12 2004-06-03 Mercury Therapeutics, Inc. Xanthene compounds for cancer chemotherapy
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
MXPA05009687A (es) 2003-03-11 2005-10-20 Novartis Ag Uso de derivados de isoquinolina para tratar cancer y enfermedades relacionadas con cinasa map.
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
WO2005007616A1 (en) 2003-07-23 2005-01-27 Warner-Lambert Company Llc Diphenylamino ketone derivatives as mek inhibitors
CA2532067C (en) 2003-07-24 2010-12-21 Stephen Douglas Barrett N-methyle-substituted benzamidazoles
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP1674452A4 (en) 2003-09-19 2007-10-10 Chugai Pharmaceutical Co Ltd NEW 4-PHENYLAMINOBENZALDOXIMDERIVATIE AND ITS USE AS MEK INHIBITOR
MXPA06004236A (es) * 2003-10-16 2006-06-28 Chiron Corp Benzazoles sustituidos y su uso como inhibidores de raf-cinasa.
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
RS50569B (sr) 2004-06-11 2010-05-07 Japan Tobacco Inc. Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido (2,3-d)pirimidina i slična jedinjenja za lečenje raka
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
WO2006018188A2 (en) 2004-08-17 2006-02-23 F. Hoffmann-La Roche Ag Substituted hydantoins
CN101006085A (zh) 2004-08-17 2007-07-25 霍夫曼-拉罗奇有限公司 取代的乙内酰脲类
CN101044125A (zh) 2004-08-25 2007-09-26 塔尔基公司 杂环化合物和应用方法
EP1799656A4 (en) 2004-08-25 2009-09-02 Targegen Inc HETEROCYCLIC COMPOUNDS AND METHODS OF USE
MX2007002433A (es) 2004-09-01 2007-05-04 Astrazeneca Ab Derivados de quinazolinona y su uso como inhibidores de b-raf.
JP2006083133A (ja) 2004-09-17 2006-03-30 Sankyo Co Ltd スルファミド誘導体医薬組成物
TW200621766A (en) 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
ZA200703912B (en) 2004-10-20 2008-09-25 Serono Lab 3-arylamino pyridine derivatives
JP2008520615A (ja) 2004-11-24 2008-06-19 ラボラトワール セローノ ソシエテ アノニム 過増殖性障害を処置するためのｍｅｋ阻害剤としての新規４−アリールアミノピリドン誘導体
ES2330872T3 (es) 2004-12-01 2009-12-16 Merck Serono Sa Derivados de (1,2,4)triazolo(4,3-a)piridina para el tratamiento de enfermedades hiperproliferativas.
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
TW201238952A (en) 2005-05-18 2012-10-01 Array Biopharma Inc Heterocyclic inhibitors of MEK and methods of use thereof
WO2006133417A1 (en) 2005-06-07 2006-12-14 Valeant Pharmaceuticals International Phenylamino isothiazole carboxamidines as mek inhibitors
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
EP1912636B1 (en) 2005-07-21 2014-06-25 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
EA032466B1 (ru) 2005-10-07 2019-05-31 Экселиксис, Инк. Способы получения ингибиторов mek
CN101341132A (zh) 2005-12-21 2009-01-07 阿斯利康(瑞典)有限公司 作为mek抑制剂用于治疗癌症的6-(4-溴-2-氯-苯基氨基)-7-氟-n-(2-羟基乙氧基)-3-甲基-3h-苯并咪唑-5-甲酰胺的甲苯磺酸盐
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
CN101415689A (zh) * 2006-04-05 2009-04-22 阿斯利康(瑞典)有限公司 具有抗癌活性的经取代的喹唑啉
WO2007121269A2 (en) 2006-04-11 2007-10-25 Ardea Biosciences, Inc. N-aryl-n'alkyl sulfamides as mek inhibitors
AU2007237901B2 (en) 2006-04-18 2012-07-05 Ardea Biosciences, Inc. Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors
CN101426766B (zh) 2006-04-19 2014-03-26 默克雪兰诺有限公司 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物
US7772233B2 (en) 2006-04-19 2010-08-10 Merck Serono, S.A. Arylamino N-heteroaryl compounds as MEK inhibitors
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
WO2008020203A1 (en) 2006-08-17 2008-02-21 Astrazeneca Ab Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors
AU2007286807B2 (en) 2006-08-21 2013-03-21 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
MX2009001878A (es) 2006-08-21 2009-03-03 Genentech Inc Compuestos de aza-benzofuranilo y metodos de uso.
WO2008028141A2 (en) 2006-08-31 2008-03-06 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
WO2008055236A2 (en) 2006-10-31 2008-05-08 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
WO2008067481A1 (en) 2006-11-30 2008-06-05 Genentech, Inc. Aza-indolyl compounds and methods of use
CN111643496A (zh) 2006-12-14 2020-09-11 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
WO2009002607A1 (en) * 2007-05-01 2008-12-31 Dana-Farber Cancer Institute, Inc. Compositions and methods for identifying transforming and tumor suppressor genes
CA2694646C (en) * 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
ES2986037T3 (es) * 2009-10-16 2024-11-08 Novartis Ag Combinación que comprende un inhibidor de MEK y un inhibidor de B-Raf

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1803821A2 (en) * 2002-06-05 2007-07-04 Cedars-Sinai Medical Center Methods for managing kinase inhibitor therapy
WO2010068738A1 (en) * 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CORY M. JOHANNESSEN, JESSE S. BOEHM, SO YOUNG KIM, SAPANA R. THOMAS, LESLIE WARDWELL, LAURA A. JOHNSON, CAROLINE M. EMERY, NICOLAS: "COT drives resistance to RAF inhibition through MAP kinase pathway reactivation", NATURE, MACMILLAN JOURNALS LTD, LONDON, GB, vol. 468, no. 7326, 16 December 2010 (2010-12-16), GB, pages 968 - 972, XP002633499, ISSN: 0028-0836, DOI: 10.1038/NATURE09627 *
EMERY C M ET AL: "MEK1 mutations confer resistance to MEK and B-RAF inhibition", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 106, no. 48, 1 December 2009 (2009-12-01), US, pages 20411 - 20416, XP002569027, ISSN: 0027-8424, DOI: 10.1073/pnas.0905833106 *
MOLHOEK KERRINGTON R; BRAUTIGAN DAVID L; SLINGLUFF CRAIG L JR: "Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, vol. 3, no. 1, 28 October 2005 (2005-10-28), pages 39, XP021009887, ISSN: 1479-5876, DOI: 10.1186/1479-5876-3-39 *
POULIKOS I. POULIKAKOS, CHAO ZHANG, GIDEON BOLLAG, KEVAN M. SHOKAT & NEAL ROSEN: "RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF", NATURE, MACMILLAN JOURNALS LTD, LONDON, GB, vol. 464, no. 7287, 18 March 2010 (2010-03-18), GB, pages 427 - 431, XP002633498, ISSN: 0028-0836, DOI: 10.1038/NATURE08902 *
RAMIN NAZARIAN, HUBING SHI, QI WANG, XIANGJU KONG, RICHARD C. KOYA, HANE LEE, ZUGEN CHEN, MI-KYUNG LEE, NARSIS ATTAR, HOOMAN SAZEG: "Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation", NATURE, MACMILLAN JOURNALS LTD, LONDON, GB, vol. 468, no. 7326, 16 December 2010 (2010-12-16), GB, pages 973 - 979, XP002633500, ISSN: 0028-0836, DOI: 10.1038/NATURE09626 *
STEVEN J.M. JONES, JANESSA LASKIN, YVONNE Y. LI, OBI L. GRIFFITH, JIANGHONG AN, MIKHAIL BILENKY, YARON S. BUTTERFIELD, TIMOTHEE CE: "Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors", GENOME BIOLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 11, no. 8, 9 August 2010 (2010-08-09), GB, pages R82 - R82-12, XP002633496, ISSN: 1465-6906, DOI: 10.1186/gb-2010-11-8-r82 *
TAP WILLIAM D, GONG KE-WEI, DERING JUDY, ET AL: "Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma", NEOPLASIA, NEOPLASIA PRESS, ANN ARBOR, MI, US, vol. 12, no. 8, 1 August 2010 (2010-08-01), US, pages 637 - 649, XP002633497, ISSN: 1522-8002, DOI: 10.1593/NEO.10414 *

Also Published As

Publication number Publication date
JP5985401B2 (ja) 2016-09-06
BR112012022801B8 (pt) 2019-10-29
US20210404014A1 (en) 2021-12-30
JP2013526843A (ja) 2013-06-27
KR20120139767A (ko) 2012-12-27
MX343368B (es) 2016-11-01
CA2791247A1 (en) 2011-09-15
US20170268069A1 (en) 2017-09-21
WO2011112678A1 (en) 2011-09-15
EA201290883A1 (ru) 2013-04-30
AU2011224410A1 (en) 2012-09-20
CN103038364A (zh) 2013-04-10
EP2545187B1 (en) 2018-09-05
BR112012022801B1 (pt) 2019-10-15
US20130059851A1 (en) 2013-03-07
ES2714875T3 (es) 2019-05-30
BR112012022801A2 (pt) 2017-01-10
CA2791247C (en) 2019-05-14
US11078540B2 (en) 2021-08-03
EP2545187A1 (en) 2013-01-16
MX2012010420A (es) 2012-11-30
AU2011224410B2 (en) 2015-05-28
US12522872B2 (en) 2026-01-13

Similar Documents

Publication Publication Date Title
EA030276B1 (ru) Способы идентификации страдающих раком пациентов и лечения рака у пациентов, у которых имеется или развивается резистентность к первой терапии рака
US20150141470A1 (en) Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN111526889A (zh) 使用atr抑制剂治疗癌症的方法
US12146196B2 (en) C-RAF mutants that confer resistance to RAF inhibitors
Shelton et al. The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what’s genetics got to do with it?
JP2019512021A (ja) Ｃｄｋ４活性のマーカーとしてのｐ２７チロシンリン酸化およびそれを使用するための方法
KR101793127B1 (ko) Ret 억제제 및 egfr 억제제의 조합물을 유효성분으로 포함하는 비소세포폐암 치료용 조성물
WO2025245045A1 (en) Methods of treating lung cancer
LaPak Insights into the Function and Regulation of PAK5 in Melanoma
Carmo et al. Genetics and Biology of Glioblastoma Multiforme
Gao Identifiying oncogenic drivers in NSCLC cells harboring EGFR kinase domain mutation with resistance to EGFR TKI and mesenchymal phenotype
TW201910348A (zh) Tifa拮抗劑及其治療疾病之用途
KR20140098302A (ko) 디스코이딘 도메인 리셉터 2의 ｊｍ2 도메인의 발현 촉진제를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU